Targets › TLR3
10 programs from 9 companies in 11 trials: 7 Phase 1, 4 Phase 2; Oncology; next expected readout Dec 2026.
Transmembrane receptor that functions as a pattern recognition receptor recognizing double-stranded RNA (dsRNA), a sign of viral infection, to induce innate immune responses via downstream signaling pathways. Acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response. (UniProt, O15455)
Open in Phaseline: the race on TLR3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ashutosh Kumar Tewari | Poly-ICLC (Hiltonol®) Toll-like receptor 3 (TLR3) agonist; synthetic double-stranded RNA analog that activates i | TLR3 | Phase 2 | Prostate Cancer Patients on Active Surveillance; Prostate Cancer | Dec 2026 |
| James Felker | HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC Peptide vaccine with TLR3 agonist adjuvant targeting glioma-associated antigens | TLR3 | Phase 2 | Low Grade Glioma | Jan 2027 |
| Roswell Park Cancer Institute | Rintatolimod Toll-like receptor 3 agonist | TLR3 | Phase 2 | Prostate Adenocarcinoma | Apr 2027 |
| Roche | Autogene Cevumeran TLR3 agonist | TLR3 | Phase 2 | Muscle-invasive Urothelial Carcinoma | Nov 2027 |
| Joachim Aerts, MD PhD | Rintatolimod Toll-like receptor 3 agonist | TLR3 | Phase 1 | Metastatic Pancreatic Cancer | Dec 2026 |
| Robert Edwards | Rintatolimod Toll-like receptor 3 agonist | TLR3 | Phase 1 | Ovarian Cancer Recurrent | Jan 2027 |
| Washington University School of Medicine | Poly-ICLC Toll-like receptor 3 (TLR3) agonist - adjuvant | TLR3 | Phase 1 | Pancreas Cancer | Oct 2027 |
| Finn, Olivera, PhD | Hiltonol® (POLY-ICLC) Synthetic dsRNA viral mimic and toll-like receptor 3 (TLR3) agonist; host-defense activato | TLR3 | Phase 1 | Ductal Carcinoma in Situ | Feb 2028 |
| Adilia Hormigo | Poly-ICLC (Hiltonol®) Toll-like receptor 3 (TLR3) agonist and RIG-I-like receptor agonist - immune adjuvant | TLR3, RIG1 | Phase 1 | Glioblastoma | May 2029 |
| Washington University School of Medicine | Poly ICLC Toll-like receptor 3 (TLR3) agonist / innate immune activator | TLR3 | Phase 1 | Muscle-Invasive Bladder Carcinoma | Jan 2030 |
Low Grade Glioma (1) Prostate Adenocarcinoma (1) Ductal Carcinoma in Situ (1) Muscle-Invasive Bladder Carcinoma (1) Prostate Cancer Patients on Active Surveillance (1) Prostate Cancer (1) Glioblastoma (1) Muscle-invasive Urothelial Carcinoma (1) Pancreas Cancer (1) Ovarian Cancer Recurrent (1) Metastatic Pancreatic Cancer (1)
mixed (8), protein or peptide (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.